Vor Biopharma INC.
Forward trial catalysts linked to VOR
CSA tracks 1 forward catalyst for Vor Biopharma INC. across 1 asset, spanning Phase 3. The nearest is a readout expected May 2027 (month precision). Confidence across its tracked catalysts breaks down as 1 medium. Tracked indications include Generalized Myasthenia Gravis, Myasthenia Gravis, Ocular.
VOR in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Vor Biopharma INC. has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
2 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| telitacicept | NCT07249632 | Phase 3 | Recruiting | 2026-12-31 | Experimental | RemeGen Co., Ltd. | Myasthenia Gravis, Ocular |
| telitacicept | NCT06456580 catalyst | Phase 3 | Recruiting | 2027-05 | Experimental | Vor Biopharma | Generalized Myasthenia Gravis |
Every trial the CSA sample links to VOR's tracked assets, including trials another sponsor runs.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →